Compounds > kukoamine b
Page last updated: 2024-11-12

kukoamine b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kukoamine B: an anti-sepsis agent isolated from Lycium chinense; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
LyciumgenusA plant genus of the family SOLANACEAE. Members contain CEREBROSIDES and SCOPOLETIN.[MeSH]SolanaceaeA plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH]

Cross-References

ID SourceID
PubMed CID10346914
CHEBI ID81221
SCHEMBL ID15255727
MeSH IDM0557225

Synonyms (21)

Synonym
C17616
kukoamine b
CHEBI:81221
SCHEMBL15255727
AC-34135
164991-67-7
n-(3-aminopropyl)-3-(3,4-dihydroxyphenyl)-n-{4-[(3-{[3-(3,4-dihydroxyphenyl)propanoyl]amino}propyl)amino]butyl}propanamide
n-[3-[4-[3-aminopropyl-[3-(3,4-dihydroxyphenyl)propanoyl]amino]butylamino]propyl]-3-(3,4-dihydroxyphenyl)propanamide
AKOS032945996
Q27155167
FT-0686650
mfcd29904539
unii-xze94lc57w
kukoamine b mesylate
n-(3-aminopropyl)-3-(3,4-dihydroxyphenyl)-n-(4-((3-(3-(3,4-dihydroxyphenyl)propanamido)propyl)amino)butyl)propanamide
HY-N2393
CS-0022595
benzenepropanamide, n-(3-aminopropyl)-n-(4-((3-((3-(3,4-dihydroxyphenyl)-1-oxopropyl)amino)propyl)amino)butyl)-3,4-dihydroxy-
XZE94LC57W ,
n-(3-aminopropyl)-n-(4-((3-((3-(3,4-dihydroxyphenyl)-1-oxopropyl)amino)propyl)amino)butyl)-3,4-dihydroxybenzenepropanamide
MS-29817

Research Excerpts

Overview

Kukoamine B (KB) is a novel cationic alkaloid that interferes with LPS binding to TLR4.

ExcerptReferenceRelevance
"Kukoamine B (KB) is a novel cationic alkaloid that interferes with LPS binding to TLR4."( Kukoamine B promotes TLR4-independent lipopolysaccharide uptake in murine hepatocytes.
Chen, Q; Fan, S; Liu, X; Lu, Y; Wang, N; Yang, D; Yang, Y; Zheng, J; Zheng, X, 2016)		2.6

Toxicity

ExcerptReferenceRelevance
"Of 44 patients enrolled, adverse events occurred in 28 patients [n = 20, 66."( Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial.
Chen, S; Dong, K; Du, B; Feng, Y; Hu, P; Hu, XY; Hu, Z; Jiang, W; Jin, C; Liu, H; Sun, Y; Wang, CY; Wang, D; Wang, H; Wang, T; Yao, X; Zang, B; Zhang, W; Zhao, Q; Zhou, J, 2023)		1.16
"In patients with sepsis-induced organ failure, KB was safe and well tolerated."( Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial.
Chen, S; Dong, K; Du, B; Feng, Y; Hu, P; Hu, XY; Hu, Z; Jiang, W; Jin, C; Liu, H; Sun, Y; Wang, CY; Wang, D; Wang, H; Wang, T; Yao, X; Zang, B; Zhang, W; Zhao, Q; Zhou, J, 2023)		1.16
" Primary endpoints were adverse events (AEs), and the secondary endpoints were PK parameters of the first administration and the last administration."( Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study.
Chen, S; Cui, C; Dong, K; Hu, P; Jiang, J; Jin, C; Li, L; Liu, H; Wang, H; Wang, T; Wang, Z; Zhao, Q; Zhong, W, 2023)		0.91
" Treatment-related adverse events (TRAEs) occurred in 8 (44."( Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study.
Chen, S; Cui, C; Dong, K; Hu, P; Jiang, J; Jin, C; Li, L; Liu, H; Wang, H; Wang, T; Wang, Z; Zhao, Q; Zhong, W, 2023)		0.91
"24 mg/kg are safe and tolerable in healthy volunteers."( Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study.
Chen, S; Cui, C; Dong, K; Hu, P; Jiang, J; Jin, C; Li, L; Liu, H; Wang, H; Wang, T; Wang, Z; Zhao, Q; Zhong, W, 2023)		0.91

Pharmacokinetics

ExcerptReferenceRelevance
"To assess the appropriateness of the body weight or fixed dosing regimen, a population pharmacokinetic (PopPK) model of kukoamine B has been built in sepsis patients."( Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation.
Chen, S; Deng, C; Dong, K; Du, B; Hu, P; Hu, X; Jiang, J; Jin, C; Qin, H; Wang, H; Wang, T; Zhao, Q, 2022)		1.28
" Primary endpoint was safety, and secondary endpoints included pharmacokinetic (PK) parameters, changes in inflammatory mediators' level, and prognostic parameters."( Safety, tolerability, pharmacokinetics, and efficacy of kukoamine B in patients with sepsis: A randomized phase IIa trial.
Chen, S; Dong, K; Du, B; Feng, Y; Hu, P; Hu, XY; Hu, Z; Jiang, W; Jin, C; Liu, H; Sun, Y; Wang, CY; Wang, D; Wang, H; Wang, T; Yao, X; Zang, B; Zhang, W; Zhao, Q; Zhou, J, 2023)		1.16
" This study aims to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of multiple doses of KB in healthy volunteers."( Safety, Tolerability, and Pharmacokinetics of Kukoamine B in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Phase I Study.
Chen, S; Cui, C; Dong, K; Hu, P; Jiang, J; Jin, C; Li, L; Liu, H; Wang, H; Wang, T; Wang, Z; Zhao, Q; Zhong, W, 2023)		0.91

Dosage Studied

ExcerptRelevanceReference
"To assess the appropriateness of the body weight or fixed dosing regimen, a population pharmacokinetic (PopPK) model of kukoamine B has been built in sepsis patients."( Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation.
Chen, S; Deng, C; Dong, K; Du, B; Hu, P; Hu, X; Jiang, J; Jin, C; Qin, H; Wang, H; Wang, T; Zhao, Q, 2022)		1.28
"24 mg/kg group on the body weight or the fixed dosing regimen."( Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation.
Chen, S; Deng, C; Dong, K; Du, B; Hu, P; Hu, X; Jiang, J; Jin, C; Qin, H; Wang, H; Wang, T; Zhao, Q, 2022)		1.07
"Based on the simulation results, a fixed dosing regimen was recommended in the subsequent clinical trials."( Fixed dosing of kukoamine B in sepsis patients: Results from population pharmacokinetic modelling and simulation.
Chen, S; Deng, C; Dong, K; Du, B; Hu, P; Hu, X; Jiang, J; Jin, C; Qin, H; Wang, H; Wang, T; Zhao, Q, 2022)		1.07
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amineA compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's11 (64.71)24.3611
2020's6 (35.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.64 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index27.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (17.65%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (82.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
catechol
[no description available]		2.2510catecholsallelochemical;
genotoxin;
plant metabolite
spermine
[no description available]		6.17152polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
acetovanillone
apocynin : An aromatic ketone that is 1-phenylethanone substituted by a hydroxy group at position 4 and a methoxy group at position 3.		2.1110acetophenones;
aromatic ketone;
methyl ketone		antirheumatic drug;
EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug;
plant metabolite
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.5220dialdehydebiomarker
n-methylaspartate
N-Methylaspartate: An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA).. N-methyl-D-aspartic acid : An aspartic acid derivative having an N-methyl substituent and D-configuration.		2.1110amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
thermospermine
thermospermine: polyamine extracted from an extreme thermopile, Thermus thermophilus; structure. thermospermine : Propane-1,3-diamine in which a hydrogen attached to one nitrogen is substituted by a 3-aminoprop-1-yl group, and a hydrogen attached to the other nitrogen is substituted by a 4-aminobut-1-yl group. A polyamine natural product, its name arises from its similarity to spermine and the fact that it was first isolated from the extreme thermophile, Thermus thermophilus.		2.610polyazaalkane;
tetramine
kukoamine a
kukoamine A: inhibits Crithidia fasciculata trypanothione reductase; structure given in first source		8.1840amine
dizocilpine maleate
Dizocilpine Maleate: A potent noncompetitive antagonist of the NMDA receptor (RECEPTORS, N-METHYL-D-ASPARTATE) used mainly as a research tool. The drug has been considered for the wide variety of neurodegenerative conditions or disorders in which NMDA receptors may play an important role. Its use has been primarily limited to animal and tissue experiments because of its psychotropic effects.. dizocilpine maleate : A maleate salt obtained by reaction of dizocilpine with one equivalent of maleic acid.		2.1110maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
mocetinostat
mocetinostat: undergoing phase II clinical trials for treatment of cancer. mocetinostat : A benzamide obtained by formal condensation of the carboxy group of 4-({[4-(pyridin-3-yl)pyrimidin-2-yl]amino}methyl)benzoic acid with one of the amino groups of benzene-1,2-diamine. It is an orally active and isotype-selective HDAC inhibitor which exhibits antitumour activity (IC50 = 0.15, 0.29, 1.66 and 0.59 muM for HDAC1, HDAC2, HDAC3 and HDAC11).		2.110aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
cytochrome c-t
Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.		2.1110
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		03.811
Blood Poisoning
[description not available]		05.3362
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		05.3362
Age-Related Osteoporosis
[description not available]		02.2110
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		02.2110
Acute Confusional Senile Dementia
[description not available]		02.2510
Diabetes Mellitus, Adult-Onset
[description not available]		02.2510
Alzheimer Disease
A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)		02.2510
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.7830
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.5320
Innate Inflammatory Response
[description not available]		02.1310
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.1310